Trials / Approved For Marketing
Approved For MarketingNCT01683110
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cabozantinib |
Timeline
- First posted
- 2012-09-11
- Last updated
- 2013-01-16
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01683110. Inclusion in this directory is not an endorsement.